Potential strategy to treat COVID-19-related cytokine storms identified
Researchers have found that neutralising antibodies for the TNF-alpha and IFN-gamma cytokines can prevent death from SARS-CoV-2 in mice.
List view / Grid view
Researchers have found that neutralising antibodies for the TNF-alpha and IFN-gamma cytokines can prevent death from SARS-CoV-2 in mice.
Researchers have found that the PI3K signalling pathway could be targeted to prevent liptoxicity and combat obesity.
Researchers have identified hepatitis C drugs that can inhibit the SARS-CoV-2 main protease, which enables the coronavirus to reproduce.
Researchers have found that CBD induces an enzyme with antioxidant and anti-inflammatory properties in the top layer of the skin.
Hamster challenge study results suggests the oral COVID-19 vaccine induces a robust immune response, protecting the animals from infection.
Researchers have discovered new drug compounds that target the SKI complex of SARS-CoV-2, preventing replication.
The tool uses interactive molecular dynamics simulations in virtual reality (iMD-VR) to allow researchers to step inside SARS-CoV-2 enzymes and visualise molecules binding to them.
The molecular structure of the SARS-CoV-2 Envelope protein has been identified by researchers using nuclear magnetic resonance.
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.
Researchers have shown that the internal clock controls the regenerative mechanism behind beta cells in diabetic mice.
The SARS-CoV-2 RNA genome structure has been studied by researchers who identified several potential drug targets.
A new single-use, closed-system upstream bioprocess has been developed which enables the production of large number of haematopoietic stem cells and progenitor cells.
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.
Scientists have developed a new antibody-drug conjugate (ADC), made from ICAM1, an antibody that targets pancreatic cancer and the cytotoxic drug DM1 (mertansine).